% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

papaalien2000 9 posts  |  Last Activity: Sep 25, 2015 7:48 AM Member since: Jun 16, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to


    by cashbar1 Jun 16, 2015 2:41 PM
    papaalien2000 papaalien2000 Jul 9, 2015 1:25 PM Flag

    Glad, as you know, I am not a fan of Leiden, but I guess the depressed sp is not his fault. Motley fool's comment nailed it:

    "Even if you want to argue that efficacy should be closer to what was seen in the short Orkambi phase 2 trial (809-102), it's still not as impressive as what Kalydeco can do in the patient populations the drug can treat.

    The increased number of patients eligible to take Orkambi and the lower efficacy are likely the reason tat Vertex priced Orkambi at $259,000 per year, a sizable discount to Kalydeco.

    How big the discounts ultimately end up being will eventually determine the peak sales for Orkambi. Until we get a few quarters into the launch, the gross-to-net discount may hang over Vertex like a black swan."

    We need to see the first numbers of Orkambi sales before sp will recover. Increased forecast in the next quarterly cc might help.

  • Reply to

    Historic Day

    by mblock66 Jul 24, 2015 12:00 PM
    papaalien2000 papaalien2000 Jul 25, 2015 8:56 AM Flag

    this has been my strongest concern for quite some time (years!):
    wonder when they will bring more compounds to the clinic. The cancer candidates seem to be locked up in phase I and do not really fit Leiden's strategy to focus on orphan drugs.

  • Reply to

    Historic Day

    by mblock66 Jul 24, 2015 12:00 PM
    papaalien2000 papaalien2000 Jul 26, 2015 5:21 AM Flag

    Q, there is no doubt that Kalydeco and Orkambi are major achievements in treatment of CF that are a blessing for many patients. But that doesn't relief management from shaping the future of the company and to create a sustainable stream of revenue. In my opinion, VRTX has not offered much information others than referring to announcements to be made in the coming years. Second generation correctors were supposed to enter clinic in 2014. Where are they? Galapagos has a better version of Kalydeco in the clinic. Where is VRTX back-up for Kalydeco? Where are clinical candidates outside CF? Why go after cancer candidates that improve chemotherapy when the company's focus is on orphan drugs?

    I am a long time investor in VRTX, cost average of my shares is below $20, so I do not complain about my capital gain, but I dare to criticize the management of the company I am invested in when I feel somethings missing.

  • Reply to

    2nd quarter Conference call

    by qdelfan Jul 29, 2015 11:28 PM
    papaalien2000 papaalien2000 Jul 30, 2015 7:36 AM Flag

    J. Leiden: " The residual function arm always had in it both a placebo and ivacaftor monotherapy compared with 661 plus ivacaftor."

    I was not aware of iva mono versus iva+661, to me it seems that FDA asked for that arm, given their doubt on Orkambi

  • Reply to

    2nd quarter Conference call

    by qdelfan Jul 29, 2015 11:28 PM
    papaalien2000 papaalien2000 Jul 31, 2015 1:56 PM Flag

    I stand corrected, seems that I get lost on the specific design of the different arms of the ongoing trials.

  • Reply to

    shire buying baxalta

    by harvey_smiths Aug 4, 2015 9:19 AM
    papaalien2000 papaalien2000 Aug 5, 2015 7:14 AM Flag

    without info on the non-cf pipeline it is not possible to give a substantiated guess on a buy-out offer. My wild guess is somewhere between $170 and $200 - if an offer will be made, which I doubt.

  • papaalien2000 papaalien2000 Sep 22, 2015 11:35 AM Flag

    don't blame the politicians, nobody can justify what Turing did, raise the price of an old drug from $13.5 to $750!

  • papaalien2000 by papaalien2000 Sep 23, 2015 3:03 PM Flag

    VRTX sp performance during the last month compared to other big biotech's indicates indeed that "the market" is expecting major negative information, Clintons initiative certainly can not explain the steep decline in sp, VRTX is not affected by reduction on patent extensions for biologics, let's see what next cc will bring

  • papaalien2000 by papaalien2000 Sep 25, 2015 7:48 AM Flag

    today's news opens the door to a substantial market for orkambi,
    might see a change of direction for the sp today ;-)

115.18+7.95(+7.41%)Oct 2 4:00 PMEDT